The classic Starling principle proposed that microvascular fluid exchange was determined by a balance of hydrostatic and oncotic pressures relative to the vascular wall and this movement of water was regulated by gaps in the intercellular spaces. However, current literature on the endothelial glycocalyx (a jelly-like protective layer covering the luminal surface of the endothelium) has revised Starling's traditional concepts. This article aims to summarise the literature on the glycocalyx related to its basic science, clinical settings inciting injury, protective strategies and clinical perspectives. Perioperative damage to the glycocalyx structure can increase vascular permeability leading to interstitial fluid shifts, oedema, and increased surgical morbidity. Pathological shedding of the glycocalyx occurs in response to mechanical cellular stress, endotoxins, inflammatory mediators, atrial natriuretic peptide, ischaemia-reperfusion injury, free oxygen radicals and hyperglycaemia. Increased understanding of the endothelial glycocalyx may change perioperative fluid management, and therapeutic strategies aimed at its preservation may improve patient outcomes.
The endothelium has long been regarded as a selective but static physical barrier that maintained vascular wall permeability and this was supported by Starling's Law of capillary exchange in 1896. However, the endothelium has a wide range of functions: filtration of vascular fluids and macromolecules, regulation of vascular tone, and in haemostasis, neutrophil recruitment and hormone trafficking. The presence of a protein layer on the luminal surface of the endothelium was proposed by Danelli in 1940 and was first visualised in 1966 under the electron microscope as an irregular, fluffy layer extending just 20 nm into the vascular lumen 1 . Thirty years later, Vink and Duling characterised a much thicker structure in vivo (0.4 to 0.5 µm) using intravital microscopy 2, 3 . It is now known that the endothelial luminal surface is covered by a protective 'jelly-like' layer known as the glycocalyx (literally 'sweet husk'). The human systemic glycocalyx volume is estimated to be about 1700 ml 4 .
While the endothelial glycocalyx is involved in important physiological (regulation of the flow of nutrients, diverse biologically active molecules and blood cells) and pathological (inflammation, sepsis, acute lung injury and ischaemic heart disease) processes, many clinicians may not be aware of recent advances in the understanding of its role or the clinical implications of its disturbance.
This aim of this narrative literature review is to review the basic science of the endothelial glycocalyx and its clinical implications related to its biological functions, damage, regeneration and protection. Common pathophysiological processes in the perioperative setting can acutely degrade the glycocalyx and generate an adverse milieu for the surgical patient, so the important questions addressed here are what measures can be employed at the bedside to preserve this layer and what are the clinical implications of targeting the glycocalyx?
Search strategy and selection criteria
A literature search was conducted using MEDLINE (PubMed) with the aim of identifying English language articles published between January 1985 and May 2016. The following search words were used: "Endothelial glycocalyx, glycosaminoglycans, endothelium, ischaemia, atrial natriuretic peptide, albumin, hydrocortisone and matrix metalloproteases". A total of 835 articles were retrieved. Articles addressing both basic science and clinical implications of an altered glycocalyx, including measures to preserve or restore the structure were selected. The authors examined the articles in terms of quality and relevance to the practice of perioperative medicine. As a result a total of 138 articles concerning composition, physiology, injury, and preservation or restoration of the glycocalyx were included in this review.
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Composition
The glycocalyx is a dynamic and complex biochemical structure consisting of proteoglycans, glycoproteins and soluble proteins [5] [6] [7] . Proteoglycans and glycoproteins anchor the glycocalyx to the endothelium and form an extensive matrix containing soluble components. Proteoglycans, principally the core protein groups of syndecans and glypicans, readily bind glycosaminoglycan (GAG) chains, including heparan sulphates, chondroitin sulphates, dermatan sulphates and hyaluronans. Heparan sulphates account for 50% to 90% of all proteoglycans within the glycocalyx 8 . The non-sulphated, non-covalent-bound hyaluronans contribute to important functions involving the cytosolic aspect of the glycocalyx, including vascular permeability and mediation of shear stress 9 . Syndecans and glypicans are the major protein core families of heparan sulphate. The syndecans assist in the organisation of the cytoskeleton whereas the glypicans bind to the plasma membrane.
Hyaluronans bind to proteins on the endothelial cell membrane, such as CD44, and traverse the glycocalyx to provide structural support 10 . The precise number, type and sulphation pattern of the GAG chains within the glycocalyx are controlled by physiological (and pathological) stimuli, generating substantial biochemical heterogeneity. GAG side chains contain numerous ligand-binding sites and subtle changes to these chains can cause important changes in composition and function. Hyaluronic acid obtains its negative charge from carboxyl groups and provides it with exceptional hydration properties.
The glycocalyx interacts with several plasma constituents (albumin and orosomucoid) to form a thicker, physiologically active layer known as the endothelial surface layer (ESL) 6 . The ESL is several hundred nanometres thick (up to 8 µm in some larger blood vessels) [11] [12] [13] . The entire makeup of the ESL continually changes, with a dynamic process (destruction and re-synthesis) occurring at the interface between flowing blood and soluble components within the ESL 6, 11 (Figure 1 ).
Sphingosine-1-phosphate (SIP), a soluble sphingolipid synthesised by red blood cells, regulates the composition of the glycocalyx and the intercellular junctions. SIP, delivered by plasma albumin and high density lipoprotein (HDL), stabilises the glycocalyx cytoskeleton by regulating its key structural components.
Several enzymes such as hyaluronidase and matrix metalloproteases (MMPs) degrade component molecules of the glycocalyx 14 , causing marked changes in the biophysical properties of the ESL. This emphasises the importance of the ESL as a single functional entity. Interestingly, a recent study evaluating glycocalyx stability after enzymatic deletion of individual GAGs found no destabilising effect on remaining structures, suggesting GAG chains acted independently of each other in mediating structural stability 15 .
Physiological role
In physiological conditions, the endothelial glycocalyx forms a protective layer of GAGs and proteoglycans with adsorbed plasma proteins covering its endothelial surface. It regulates vascular permeability, coagulation and thrombosis, interactions between the endothelial cells and circulating blood cells, and acts as a mechanosensor of fluid shear stress that controls vascular tone. The volume and the biomechanics of the endothelial glycocalyx are regulated by ionic binding, hydrogen bonds and hydrophobic/hydrophilic interactions. Shedding and synthesis of the endothelial glycocalyx are controlled by enzymes, hormones and fluid shear stress forces. Shedding of the endothelial glycocalyx leads to endothelial dysfunction resulting in deranged biomechanics, enhanced oedema formation, disrupted cell-vessel wall interactions, and a loss of fluid shear stress sensitivity.
Vascular permeability
Sitting on the luminal endothelium, the glycocalyx is uniquely primed to regulate vascular permeability and hydraulic conductance. A constant supply of SIP from red blood cells is required for the maintenance of stable vascular permeability to water and macromolecules.
The glycocalyx is not included in the traditional concept of transcapillary fluid exchange postulated by Starling in 1896 16 . Starling's equation describes the equilibrium between hydrostatic and oncotic pressures acting across the lumen of the microvasculature relative to the underlying interstitial space (the so-called Starling forces) and the net fluid flux that results from opposing forces. It was assumed that the major factors regulating filtration were tight junctions in the gaps between endothelial cells. However, though the Starling principle is not completely wrong, it is incomplete. Adamson et al 17 observed that raised interstitial oncotic pressures in the postcapillary venule of the rat resulted in only small increases in fluid filtration. Confocal imaging of albumin distribution in vivo also revealed a subglycocalyx region devoid of protein.
These observations indicated that the prevailing oncotic pressure gradient opposing fluid filtration originated across the glycocalyx and the interstitial protein concentration played little part. In other words, the 'transglycocalyx' oncotic pressure now replaces the interstitial oncotic pressure as the key force opposing fluid filtration.
Michel and Levick proposed a 'revised' Starling principle and suggested that Starling forces only be applied across the endothelial glycocalyx, which is now considered the molecular sieve for plasma proteins 18, 19 . When the endothelial glycocalyx was experimentally removed, the hydraulic permeability increased markedly ( Figure 2 ).
The revised Starling principle is summarised by the equation:
F/A = C H x [(P HV -P HI ) -σ x (π OV -π Og ) F/A = filtration rate per area; C H = hydraulic conductivity; P HV -P HI = hydrostatic pressure (P H ) gradient between vascular lumen (V) and interstitial space (I); σ= reflection coefficient; π OV -π Og = oncotic pressure gradient (π O ) between vascular lumen (V) and the subglycocalyx region (g). The hydrostatic and oncotic pressure gradients between the lumen of the blood vessel and the interstitial space depend largely on the endothelial glycocalyx. Studies that disrupted glycocalyx integrity using various enzyme-mediated degradation techniques reported increased hydraulic conductivity 20 , anionic protein flux 21 , and the fractional filtration of albumin 22 .
Using perfusion studies on isolated guinea pig hearts, Rehm et al 23 described a 'double barrier concept' of endothelial competence in which the glycocalyx and endothelial cells both contributed to an intact vascular barrier. It was demonstrated that stressing one barrier alone had relatively little effect on vascular permeability.
The glycocalyx also confers semipermeability by virtue of its electrical charge characteristics. Numerous sulphate residues on the GAG chains, especially heparan sulphate, contribute to the negative charges on the glycocalyx, which greatly favours the binding of positive charges, whilst excluding negatively charged molecules 24 . Despite its net negative charge, albumin binds to the glycocalyx 25 , and this reduces hydraulic conductivity, resists degradation and facilitates transmission of shear stress 26 .
Mechanosensor
The vascular endothelium is exposed to shear stress and blood pressure. Syndecans and glypicans on the endothelial cell surfaces transduce these mechanical stimuli into intracellular signals that control endothelial structure and functions. Syndecan-1 modulates molecules such as tubulin and alpha-actinin. The rearrangement of glycocalyx cytoskeleton results in smooth muscle cell relaxation and vasodilation mediated by endothelial nitric oxide (NO) release. Blood vessels that are relatively free of fluid shear stress have a greater permeability to macromolecules and suffer greater atherosclerosis 27 . Glycocalyx dysfunction could be the index event in the atherothrombotic process 28 and may be involved in atherosclerotic plaque fissuring and acute coronary syndromes 29 . Shear stress stimulates NO production 30 . In 2003 Weinbaum et al 31 described a glycocalyx arrangement in which 'bush-like' clusters of proteoglycans project from anchor points in the endothelial cell cytoskeleton. Mechanical distortion of the entire bush generates forces that deform the underlying cytoskeleton. This increases endothelial nitric oxide synthase (eNOS) expression, which catalyses NO production and increases hydraulic conductivity. The glycocalyx is therefore regarded as a crucial transducer that translates fluid shear stress into a cellular signal (i.e. mechanotransduction). Any changes in fluid flux secondary to fluid shear stress inherently depend on glycocalyx-mediated NO production 27 . Thus, glycocalyxmediated vasodilation is purely a mechanical phenomenon and this separates it from other modes of NO-mediated vasodilation, including vasoactive ligand-receptor interactions and activation of endothelial cell metabolic pathways 32 . When the glycocalyx was degraded by heparan sulphates 33 or hyaluronans 34 , a blockade of shear-dependent NO production (and therefore shear-dependent increases in hydraulic conductivity too) could be demonstrated. Selective depletion of chondroitin sulphates does not have the same effect 35 .
Role in cell-vessel wall interactions
The glycocalyx modulates local blood viscosity and haematocrit in the microcirculation. The thickness of the glycocalyx layer is important for vascular rheology. The glycocalyx repels red blood cells from the endothelium and shields it from leukocyte and platelet interactions. Cell adhesion molecules (selectins and integrins) project into the vascular lumen 36 and are encased within the more expansive ESL. Consequently a damaged glycocalyx results in increased leukocyte and platelet adhesion. In the hamster cremaster muscle, Vink et al used oxidised lipoproteins to degrade the ESL and this increased the number of platelet-endothelial cell interactions 37 . Using a similar approach, Henry and Duling demonstrated increased leukocyte adhesion during tumour necrosis factor alpha (TNF-α)-mediated stress 38 . Perfusion of the post-capillary venule with the chemotactic peptide fMLP (formyl-Met-Leu-Phe) stimulated inflammation, degraded the glycocalyx, promoted leukocyte-endothelial cell adhesion and increased leukocyte rolling velocity 39 . This adhesion was reversed by the addition of doxycycline, which inhibits MMP activity and stabilises the glycocalyx 14 . There was a preponderance of leukocyte adhesion molecules in the post-capillary venule 40 , suggesting that venular glycocalyx competence may be an important mediator of inflammation.
Regulation of coagulation
The glycocalyx and the endothelium have a role in coagulation and fibrinolysis. The smooth endothelium facilitates laminar blood flow and forms a profibrinolytic and antithrombotic surface mediated by antithrombin III bound to the endothelial surface.
Glycocalyx injury
An intact glycocalyx is by no means a static structure and sheds in response to numerous physiological and pathological stimuli. Pathological injury to the glycocalyx occurs in ischaemia-reperfusion, inflammation, sepsis, shock, hypervolaemia, hyperglycaemia, excessive shear stress and bypass surgery. Glycocalyx damage can vary from relatively minor perturbations of component molecules to complete dissolution of the layer. Any damage can result in adverse consequences such as increased vascular permeability and interstitial oedema, attenuated vascular responses to shear stress, platelet aggregation, leukocyte adhesion, altered microvascular rheology and generation of a prothrombotic environment.
Ischaemia-reperfusion injury
Ischaemia-reperfusion (I/R) injury causes an early disruption to the glycocalyx 41 resulting in tissue damage. Local or systemic organ dysfunction, including systemic inflammatory response syndrome 42 , occurs as a result of the underlying microvascular endothelial cell dysfunction 43 . Mulivor and Lipowsky demonstrated a marked decrease in glycocalyx GAG volume following an I/R injury to the rat mesenteric venule and this was attenuated by pretreatment with pertussis toxin (an inhibitor of G proteinmediated GAG shedding) 44 . Cardiac I/R injury is encountered during percutaneous coronary angioplasty, coronary artery bypass grafting (CABG) and heart transplant surgery 45 . The attendant glycocalyx diminution is associated with impaired endothelial-dependent coronary vasodilation, the 'no-reflow' phenomenon and interstitial oedema 46 . When Bruegger et al subjected isolated guinea pig hearts to warm ischaemia and reperfusion, electron microscopy revealed markedly reduced glycocalyx thickness and significant oedema formation 47 . During CABG surgery, injury to the glycocalyx has been demonstrated in both on-pump and off-pump surgery, suggesting I/R was not the sole factor causing shedding, and that cardiac surgery itself was an independent risk factor 48 .
Sepsis
Inflammatory mediators in sepsis cause glycocalyx shedding during inflammation, trauma and sepsis. Severe sepsis is associated with a mortality rate as high as 40%, despite advances in clinical management 49 . Pathophysiological events include capillary leakage, tissue oedema and relative hypovolaemia 50 . The proinflammatory cytokine TNF-α acutely disrupts the glycocalyx and this results in an increased vascular permeability to macromolecules 38 . In isolated guinea pig hearts, the application of TNF-α induced subtotal glycocalyx destruction, and was associated with increased coronary vascular resistance, tissue oedema, coronary leak, increased colloid permeability and mast cell degranulation 51 . Other inflammatory mediators that disrupt the glycocalyx include C-reactive protein, adenosine, bradykinin and bacterial lipopolysaccharide.
The plasma concentrations of its constituent molecules such as heparan sulphate and syndecan-1 increase when the glycocalyx is damaged. Steppan et al demonstrated glycocalyx shedding in severely septic patients and following major abdominal surgery 49 . Furthermore, the absolute plasma level of syndecan-1 is well correlated with severity of sepsis, non-survival and need for intubation in septic shock patients 52, 53 . Considerable increases in plasma concentrations of glycocalyx components were reported in pregnant women with HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome, a disseminated inflammatory disease associated with vascular leak and platelet adhesion 54 .
Hypervolaemia
Hypervolaemia can cause shedding of the endothelial glycocalyx. Liberal perioperative fluid administration resulting in a positive fluid balance is associated with increased morbidity 55 . Paradoxically, when colloid solutions (5% human albumin and 6% hydroxyethylstarch) are infused in normovolaemic patients, about 60% of the colloid almost immediately extravasates into the interstitial space. The same colloids administered in the setting of acute normovolaemic haemodilution remain almost entirely within the intravascular space 56, 57 . Fluid preloading to pre-empt blood loss by 'overfilling' the intravascular compartment is therefore not recommended. The different fates of colloids can be explained by the relationship between hypervolaemia and glycocalyx thickness. Atrial natriuretic peptide (ANP) is released in response to fluid shear stress induced by hypervolaemia, such as that seen following rapid infusion of two litres of crystalloid solution 58 . ANP is known to increase microvascular permeability but its role on the glycocalyx function has only been recognised recently. In animal models, the application of ANP results in rapid shedding of the glycocalyx, a process mediated by a cyclic GMP-linked proteolytic pathway. This results in an increase in net fluid filtration and colloid extravasation 59 . A study showed that an intracoronary infusion of physiological concentrations of A-, B-and C-type natriuretic peptides caused dose-dependent glycocalyx shedding associated with increased vascular permeability 60 . ANP release may also be responsible for glycocalyx shedding observed in both on-pump and off-pump CABG surgery 61 .
Blood loss
Animal models of haemorrhagic shock have demonstrated glycocalyx shedding 62, 63 but the mechanism of this phenomenon is unknown. Kozar et al showed that bowel mesentery venules lost significant glycocalyx volume when rats were subjected to bloodletting and hypotension (mean arterial pressure of 30 mmHg for 90 minutes). When blood pressure was then restored using plasma (mean arterial pressure of 80 mmHg for two hours), these changes were partially reversed, but not when lactated Ringer's solution was used. The authors suggested that the survival benefit associated with plasma resuscitation in massive haemorrhage may be due to recovery of the glycocalyx 63 . In another animal model, a 40% reduction in blood volume caused a 59% reduction in glycocalyx thickness 62 . Therefore, glycocalyx injury appears to be a key component of haemorrhagic shock.
Hyperglycaemia
Recent evidence from animal models and clinical studies suggests both acute and chronic hyperglycaemia can cause glycocalyx damage. Cardiovascular complications are a major cause of mortality in patients with diabetes mellitus 64 , but the exact causal relationship has not been fully elucidated. The 'Steno hypothesis' 65 suggested a role for heparan sulphates in the development of diffuse vascular damage observed in diabetic patients.
Zuurbier et al subjected anaesthetised C57BL/6 mice to acute hyperglycaemia (25 mmol/l for 60 minutes and for two to four weeks), demonstrating a sustained increase in glycocalyx permeability (despite an unchanged glycocalyx volume) 66 . Nieuwdorp et al subjected healthy volunteers to six hours of 15 mmol/l hyperglycaemia and found a loss of approximately half of total glycocalyx volume compared with controls, and this was ameliorated by concomitant infusion of the antioxidant N-acetylcysteine 4 . Both studies concluded that hyaluronans critically maintain the permeability barrier and are the vulnerable component in acute hyperglycaemia.
Chronic hyperglycaemia is also associated with glycocalyx injury. A study investigating the effects of type 1 diabetes mellitus on the glycocalyx found that diabetic patients (HbA 1c levels between 7.0% and 9.0%) had systemic glycocalyx volumes approximately half that of age-matched controls. The combination of type 1 diabetes mellitus and microalbuminuria was more destructive, with these patients losing three-quarters of systemic glycocalyx volume compared with controls 67 . It has been postulated that glycocalyx damage actually causes microalbuminuria in patients with diabetes mellitus 32, 68 . Broekhuizen et al recently examined two microcirculations in patients with type 2 diabetes mellitus and found significant perturbation of the glycocalyx (increased extravasation of albumin) compared with age-matched controls 69 . The authors also showed that oral sulodexide (a glycosaminoglycan that includes heparan and dermatan sulphate) increased glycocalyx thickness, indicating that glycocalyx destruction was reversible.
An impaired glycocalyx with elevated plasma levels of constituent molecules has been found in renal dialysis patients 70 . Furthermore, both acute and chronic hyperglycaemia are associated with increased thrombotic events (independent of coexisting atherosclerosis). This may be partly due to glycocalyx shedding leading to increased platelet-endothelial cell interactions 71 .
The precise process connecting hyperglycaemia and glycocalyx disruption is unknown. In a recent review article, Lemkes et al 72 postulated that hyperglycaemia led to the formation of reactive oxygen species, which damaged the glycocalyx by both a direct effect on GAG chains as well as indirectly via activation of intracellular pathways. The observed glycocalyx-sparing effects of N-acetylcysteine, a potent antioxidant, make this an attractive hypothesis. Hyperglycaemia also modulates the sulphation of GAG chains (the basis of the Steno hypothesis), or decreases the number of GAG chains present on the core protein. In addition, hyaluronan binding to the glycocalyx is disrupted in hyperglycaemic states (plasma glucose concentration >10 mmol/l). As well, hyperglycaemia can increase inflammatory mediators associated with advanced glycation end products (AGE, a glycoprotein). Heparin can prevent the binding of AGE to their receptors 73 .
Strategies of protection of the glycocalyx (glycocalyx priming)
In the perioperative period, strategies to protect or restore the glycocalyx are clearly appealing, especially considering recovery is a slow process. Using a rat model, Potter et al showed that five to seven days were required for complete 'healing' of the glycocalyx 74 . The need for clinical trials to demonstrate strategies that specifically protect the glycocalyx has been emphasised 75, 76 .
Fluid therapy
Fluid management is still a controversial topic. The pharmacological differences between crystalloids and colloids are still largely based on Starling's principle. In the past decade, the glycocalyx has received increasing attention as a "new molecular player in the great fluid debate" 77 . Crystalloids freely pass through the glycocalyx whereas colloids are retained within the vasculature by this structure. Numerous retrospective studies reported a survival benefit when a high ratio of fresh frozen plasma to red cell resuscitation was employed during [78] [79] [80] [81] [82] [83] , and after 63 , massive transfusion. This may be explained by the protection or regeneration of the glycocalyx. Many clinical and research observations following administration of intravenous fluid therapy 18, 84, 85 can be explained by incorporating the glycocalyx into Starling's principle. The effects of volume loading to preferentially expand the intravascular space in normovolaemic patients is negated by glycocalyx shedding, resulting in increased vascular permeability. Acute hypervolaemic haemodilution causes mechanical stress and natriuretic peptide-mediated glycocalyx injury, and this can explain why fluids administered in this setting are largely lost to the interstitial space 57 .
Generous volume loading is still advocated prior to general and neuraxial anaesthesia to maintain adequate tissue perfusion and improve postoperative outcomes [86] [87] [88] [89] [90] [91] . However, this practice may cause iatrogenic glycocalyx shedding and promote interstitial oedema resulting in tissue hypoperfusion 50 . In one study, postoperative weight gain associated with fluid therapy occurred in 40% of surgical patients admitted to the intensive care unit, and prolonged postoperative ventilation and increased vasopressor requirements and mortality were demonstrated 92 . Liberal intraoperative fluid therapy is now rarely practised because the traditional concept that routine preoperative fasting causes significant hypovolaemia may not be valid 93 . Preloading with intravenous fluids did not decrease the incidence of hypotension or reduce the vasopressor requirements following central neuraxial anaesthesia in several studies 94, 95 . Again, this may be explained by the release of ANP during the transient hypervolaemic state, which degrades the glycocalyx and results in increased leakage into the interstitial space. Indeed, the volume effect of isotonic colloid solutions exceeds 90% when it is used solely as a replacement for acute blood loss 56, 96 . Finally, the extent of insensible fluid loss in the perioperative period may have been overstated; even during open abdominal surgery the evaporative rate may be as low as 1 ml/kg/hour 97 .
The principles guiding fluid therapy are to (i) maintain central euvolaemia, and (ii) avoid water and salt excess in the perioperative period. A 'context sensitive' approach to fluid therapy takes into account the pharmacokinetics of intravenous fluids in different clinical settings. Some evidence from recent literature suggests that avoidance of excessive perioperative fluid administration can reduce postoperative complications. Moreover, glycocalyx-sparing 'restrictive' fluid regimens have been shown to reduce postoperative morbidity and length of hospital stay compared with 'liberal' regimens 55, 98, 99 . A zero balance approach to minimise hypervolaemia is recommended for all patients. There is also some evidence that individualised goal-directed fluid therapy improves outcomes in major abdominal surgery. Various clinical trials comparing 'restrictive' or zero balance and goal-directed fluid therapy have reported equal results, as long as fluid overload is avoided. However, the debate on perioperative fluid therapy is beyond the scope of this review and has been summarised by Miller et al 100 
Glycaemic control
Given the magnitude of glycocalyx shedding after brief exposure to hyperglycaemia 4, 66 , there is some experimental evidence that maintaining perioperative normoglycaemia can stabilise the glycocalyx. O'Hora et al evaluated the effects of insulin and metformin on glycocalyx function by measuring glycocalyx-dependent shear stress-mediated vasodilation in the anaesthetised pig 102 . The authors reported that both insulin and metformin increased arterial dilation by a direct (glycocalyx-independent) effect on NO synthesis. However, there is no clinical data and the risks of intraoperative hypoglycaemia associated with insulin therapy have to be considered. The optimal perioperative blood sugar range is considered to be 5 to 10 mmol/l and maintaining blood sugar levels within this range has other benefits such as reduced surgical site infections.
Oral sulodexide, which provides a source of the glycocalyx constituents heparan sulphate and dermatan sulphate, administered to patients with type 2 diabetes mellitus (200 mg per day for two months) increased glycocalyx thickness in retinal and sublingual microcirculations, and reduced the transcapillary escape rate of albumin 69 .
Microalbuminuria in diabetic patients indicates severe glycocalyx disruption 32, 67 and is a surrogate marker of generalised microvascular dysfunction and increased permeability 103, 104 . The triad of glycocalyx disruption, albuminuria and increased microvascular permeability also occurs in other pathological processes such as I/R and infectious diseases 103 . Therefore, experimental data indicates that glycocalyx-sparing techniques would particularly benefit this patient group. Sulodexide ameliorates proteinuria in patients with diabetes mellitus 105, 106 .
Reducing mediators associated with inflammation, sepsis and surgical stress
Targeting the glycocalyx is a promising therapeutic intervention in the management of the systemic inflammatory response 51, 107 . There is a positive correlation between the magnitude of glycocalyx disruption and mortality from sepsis. Increased plasma levels of the glycocalyx components syndecan, heparan sulphate and hyaluronan were detected in septic patients, with the highest levels found in severe sepsis and septic shock. The APACHE II (Acute Physiology and Chronic Health Evaluation), SOFA (Sequential Organ Failure Assessment) and MOD (Multiple Organ Dysfunction) scores were positively correlated with plasma levels of syndecan and hyaluronan 49, 52, 108 .
(a) Anti-TNF agents
The cytokine TNF-α has received much attention in the setting of inflammation-induced glycocalyx shedding 38, 51, 109 . Strategies to antagonise the effects of TNF-α have been described. Nieuwdorp et al subjected healthy adult volunteers to endotoxin-mediated glycocalyx destruction (1 ng/kg of Escherichia coli lipopolysaccharide), and found that pre-treatment with etanercept (a soluble TNF-α receptor blocker, 50 mg intramuscularly) attenuated the reduction in glycocalyx thickness and decreased inflammatory and coagulation responses 109 .
(b) Hydrocortisone
Chappell et al infused TNF-α into guinea pig hearts and demonstrated severe glycocalyx destruction in coronary vessels associated with significant tissue oedema. Pretreatment with hydrocortisone (dose equivalent to clinical stress) or antithrombin (at physiological plasma levels) almost entirely prevented these changes 51 . Furthermore, hydrocortisone preserved the glycocalyx in I/R models and mitigated the inflammatory effects, thus protecting against the 'low-reflow' phenomenon 41 . When administered to high-risk cardiac surgery patients, stress doses of hydrocortisone attenuated perioperative inflammatory responses and improved early postoperative outcomes [110] [111] [112] . Hydrocortisone is recommended in the Surviving Sepsis Campaign guidelines in patients with septic shock refractory to fluids and vasopressors 113 .
(c) Anaesthetic technique
Volatile anaesthetics (sevoflurane at a minimum alveolar concentration of 1) have been found to protect the glycocalyx in post-ischaemic coronary beds and improve coronary vascular function (reduced coronary resistance, less tissue oedema and reduced adhesion of leukocytes and platelets) 114, 115 . Exogenous NO may also be beneficial, protecting the glycocalyx against post-ischaemic redox stress via a radical scavenging effect 47 .
Epidural anaesthesia can partially attenuate surgical inflammatory responses and it is conceivable that the glycocalyx would benefit from such practice. Single-shot neuraxial anaesthesia, however, does not appear to dampen inflammatory responses to the same degree [116] [117] [118] .
(d) Control of stress response
Increased heart rate in critical illness is associated with deeper penetration of red cells into the endothelial surface (indicating increased glycocalyx damage) 119 . Heart rate control by a titrated esmolol infusion in septic shock patients was associated with maintenance of stroke volume, preserved microvascular blood flow, and a reduction in noradrenaline requirements 120 .
A recent study of CABG surgery reported that the administration of diazoxide to control intraoperative hypertension significantly decreased postoperative hyaluronan and syndecan-1 plasma levels compared with controls 121 , suggesting a reduction in glycocalyx damage.
Antagonising enzyme-mediated glycocalyx injury
MMPs, a family of zinc-dependent endopeptidases, degrade the glycocalyx and promote inflammation 14, 122 . Strategies that antagonise these enzymes can protect the glycocalyx. In a rodent model of inflammation, pre-treatment of tissues with subantimicrobial doses of doxycycline, a broad-spectrum MMP inhibitor, or ilomastat, a specific MMP hydroxamic acid inhibitor, reduced glycocalyx shedding and leukocyte-endothelial cell adhesion 14, 122 . Orthophenanthroline, a metal chelator and non-specific inhibitor of MMPs, applied to guinea pig hearts subjected to ANP-mediated stress, reduced glycocalyx shedding, but paradoxically, increased transudate formation 60 . These findings support the development of therapeutic strategies directed against enzyme-mediated glycocalyx damage.
Glycocalyx shedding can occur at physiological hormone concentrations; given the elevated brain natriuretic peptide concentrations in acute and chronic heart failure, monitoring the glycocalyx in these patients is warranted and could provide a novel therapeutic approach 60, 123, 124 .
Rebuilding the glycocalyx (a) Hyaluronan
As a consequence of its role in glycocalyx stability, replacement of hyaluronan is a rational method to rebuild the glycocalyx 32, 125 . In a rodent model of sepsis, intravenous hyaluronan reduced inflammatory cell chemotaxis, cytokine production and sepsis-induced lung injury 126 . Henry and Duling described a method to reconstitute the glycocalyx using a combination of exogenous hyaluronan and chondroitin sulphate following enzyme-mediated depletion in a hamster skeletal muscle model. Treatment with these GAGs improved glycocalyx dimensions but not when applied separately 127 . In the bovine lung, synthetic cationic copolymers avidly bind to the negatively charged glycocalyx and improve endothelial barrier function (measured by reduced albumin permeability and decreased hydraulic conductivity). In a glycocalyx mechanotransduction model of microvascular dysfunction and lung injury, glycocalyxdependent enhanced endothelial porosity was suppressed by cationic copolymers, indicating a promising therapeutic role for the polymers in acute lung injury and for the treatment of increased vascular permeability [128] [129] [130] .
(b) Albumin
Supplementing the ESL by providing exogenous plasma proteins is easily achieved in clinical practice. In an animal model of heart transplantation, supplementing histidinetryptophan-ketoglutarate (HTK) solution with 1% human albumin reduced glycocalyx shedding, myocardial oedema and intracoronary adhesion of leukocytes, whilst improving right heart pump function following cold ischaemia (four hour period). Traditional HTK preservation (devoid of albumin) was associated with significantly greater glycocalyx damage 131 . These findings suggest that it would be sensible to maintain physiological levels of albumin in plasma and in solutions bathing tissues, as albumin is attached to the glycocalyx 25 . Moreover, allografts require an intact ESL to resist reperfusion injury 75 . In haemorrhagic shock, plasma replacement improves glycocalyx parameters compared to resuscitation with lactated Ringer's solution 63 .
(c) Antithrombin III Antithrombin supplementation has been widely used to treat sepsis-induced disseminated intravascular coagulation (DIC), but evidence of benefit is inconclusive. A recent multicentre retrospective study suggested a trend towards reduced in-hospital all-cause mortality in patients receiving antithrombin supplementation 132 . There is need for a large randomised controlled trial to establish the role of antithrombin III in patients with critical illness, especially those with sepsis-induced DIC and without concomitant heparin administration 133 .
(d) Heparin
Heparin may preserve or protect the endothelial glycocalyx. In a septic shock model, Sun et al showed that treatment with crystalloids and antibiotics only partially reversed the glycocalyx degradation, whereas treatment with crystalloids, antibiotics and unfractionated heparin normalised the endothelial glycocalyx 134 . It was suggested that heparin either had a direct protective effect on the glycocalyx or its anti-inflammatory effects caused less organ dysfunction and thereby reduced glycocalyx shedding.
(e) Metabolic glycoengineering
While metabolic glycoengineering is an emerging technique that allows non-natural sugars to be incorporated into the glycocalyx, it could serve as a platform for discovering a whole host of new 'sugar-based drugs' 135 .
From a practical point of view maintenance of euvolaemia and normoglycaemia in the perioperative period can minimise glycocalyx shedding. Whilst the above specific agents have been shown to protect the glycocalyx in experimental models, they have not been used clinically.
Therapeutic modulation of the glycocalyx and its influence on clinical practice
For the past two decades the glycocalyx has received increasing attention, with a great deal of therapeutic promise borne out of its role in vascular health and disease. Despite the well-described pathological sequelae that follow glycocalyx damage, particularly with regard to vascular permeability and interstitial oedema, clinical benefits ascribed to the glycocalyx are unfortunately absent.
Many seemingly innocuous clinical practices challenge glycocalyx integrity, especially in the perioperative period. By inducing hypervolaemia, anaesthetists could contribute to iatrogenic glycocalyx injury and worsen outcomes. There is a body of early experimental evidence that meticulous fluid therapy, volatile anaesthesia, normoglycaemia and maintaining normal plasma albumin levels can minimise glycocalyx injury. Glycocalyx injury may be an early trigger of coronary microvascular dysfunction and ischaemic heart disease, such that measuring microvascular volume in these patients may help to stratify their future coronary risk 135 . The need to monitor the microcirculation in critical illness is well described and promisingly, a non-invasive technique to assess the glycocalyx at the bedside has been recently employed 50, 119, 137 . Statin therapy is a promising perioperative intervention: short-term administration of rosuvastatin to patients with familial hypercholesterolaemia improved systemic glycocalyx volume 138 . However, further research is required to assess the value of statins in rebuilding the glycocalyx in the perioperative period.
Experimental methods may not be easily implemented in the clinical setting and unfortunately clinical therapeutic strategies that specifically target the glycocalyx are not currently available. Heterogeneity of clinical studies aimed at restricting extravascular fluid shifts based on protection of the endothelial glycocalyx limit the strength of evidencebased interventions. However optimal clinical management, especially meticulous fluid management, may minimise glycocalyx-mediated surgical morbidity.
